SCHEMBL2541079

SCHEMBL2541079

O=C1NC(=O)C(=Cc2cc(OC(F)(F)F)ccc2F)S1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.69
PIM2 Q9P1W9 7/20 0.69
NR1H4 Q96RI1 1/20 0.59
IGF1R P08069 2/20 0.57
LMNA P02545 2/20 0.56
HPGD P15428 2/20 0.56
KMT2A Q03164 2/20 0.56
PIK3CA P42336 1/20 0.54
PIK3CG P48736 1/20 0.54
GSK3B P49841 1/20 0.49
TTR P02766 1/20 0.48
CISD1 Q9NZ45 1/20 0.48
AKR1B1 P15121 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
PTPN1 P18031 3/20 0.47
SCN9A Q15858 1/20 0.47
MEN1 O00255 1/20 0.47
PLA2G1B P04054 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2541077 1.00 PIM1 (0.69) PIM1PIM2NR1H4IGF1RLMNA
SCHEMBL2541084 0.90 PIM1 (0.69) PIM1PIM2NR1H4IGF1RLMNA
SCHEMBL2541088 0.90 PIM1 (0.69) PIM1PIM2NR1H4IGF1RLMNA
SCHEMBL2547582 0.90 PIM1 (0.69) PIM1PIM2NR1H4IGF1RLMNA
SCHEMBL2547674 0.87 PIM1 (0.69) PIM1PIM2NR1H4LMNAHPGD
SCHEMBL2547675 0.87 PIM1 (0.69) PIM1PIM2NR1H4LMNAHPGD
SCHEMBL2545582 0.85 PIM1 (0.69) PIM1PIM2NR1H4LMNAHPGD
SCHEMBL2545580 0.85 PIM1 (0.69) PIM1PIM2NR1H4LMNAHPGD
SCHEMBL14081848 0.84 GSK3B (0.68) PIM1PIM2IGF1RLMNAHPGD
SCHEMBL2541054 0.82 PIM1 (1.00) PIM1PIM2NR1H4HPGDGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US claimed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP claimed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO claimed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO claimed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US disclosed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP disclosed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO disclosed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885NR1H4 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.